Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 8 for:    vosoritide

A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04554940
Recruitment Status : Recruiting
First Posted : September 18, 2020
Last Update Posted : July 26, 2021
Sponsor:
Information provided by (Responsible Party):
BioMarin Pharmaceutical

Brief Summary:
Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery

Condition or disease Intervention/treatment Phase
Achondroplasia Biological: vosoritide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression Surgery
Actual Study Start Date : October 10, 2020
Estimated Primary Completion Date : December 2026
Estimated Study Completion Date : December 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Vosoritide + Standard of Care
Standard of Care treatment for cervicomedullary compression and once daily subcutaneous injection of vosoritide at 30μg/kg (ages 0 - <2 years old) or 15 μg/kg (ages >2 years old)
Biological: vosoritide
Subcutaneous injection of 30μg/kg (ages 0 - <2 years old) or 15 μg/kg (ages >2 years old) of vosoritide daily

No Intervention: Standard of Care Alone
Institutional standard of care monitoring and treatment for cervicomedullary compression



Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Through Week 260 ]

Secondary Outcome Measures :
  1. Evaluate the effect of Vosoritide on total foramen magnum volume (in cm3) by MRI volumetric measurement software [ Time Frame: Through Week 260 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 12 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Parent(s) or guardian(s) willing and able to provide signed informed consent after the nature of the study has been explained and prior to performance of any research related procedure.
  • Have ACH, documented by genetic testing.
  • Are willing and able to perform all study procedures as physically possible.
  • Age 0 to ≤ 12 months, at study entry (Day 1). Given that any potential impact of vosoritide therapy on the foramen magnum is dependent on treating as early as possible and as long as possible while the synchondroses at the base of the skull are still open. For subjects > 6 months of age at enrollment, a discussion between the investigator and the Medical Monitor should occur with the goal of limiting the number of subjects in the range of > 6 months to ≤ 12 months of age.
  • Parent(s) or caregiver(s) are willing to administer daily injections to the subject and complete the required training.
  • Have evidence of CMC that "may" require surgical intervention

Exclusion Criteria:

  • Have hypochondroplasia or short-stature condition other than achondroplasia (eg, trisomy 21, pseudoachondroplasia, etc).
  • Have CMC that either does not require surgical intervention (for example foramen magnum narrowing with preservation of the cerebrospinal fluid space) or does require immediate surgical intervention .
  • Have any of the following: Untreated congenital hypothyroidism or maternal history of hyperthyroidism, Insulin-requiring neonatal diabetes mellitus, Autoimmune inflammatory disease, Inflammatory bowel disease, Autonomic neuropathy.
  • Have a history of any of the following:Renal insufficiency, Chronic anemia,Baseline systolic blood pressure below age and gender specified normal range or recurrent symptomatic hypotension (defined as episodes of low blood pressure generally accompanied by symptoms eg, pallor, cyanosis, irritability, poor feeding) and Cardiac or vascular disease.
  • Have a clinically significant finding or arrhythmia that indicates abnormal cardiac function or conduction or QTc-F ≥ 450 msec on screening ECG.
  • Have been treated with growth hormone, insulin-like growth factor 1, or anabolic steroids in the 6 months prior to Screening, or long-term treatment (> 3 months) at any time.
  • Have ever had prior cervicomedullary decompression surgery.
  • Have had a fracture of the long bones or spine within 6 months prior to Screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04554940


Contacts
Layout table for location contacts
Contact: Trial Specialist 1-800-983-4587 medinfo@bmrn.com

Locations
Layout table for location information
Australia, Victoria
Murdoch Children's Research Institute Recruiting
Parkville, Victoria, Australia, 3052
United Kingdom
Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital Recruiting
London, United Kingdom, SE1 7EH
Sheffield Children's NHS Foundation Trust Recruiting
Sheffield, United Kingdom, S10 2TH
Sponsors and Collaborators
BioMarin Pharmaceutical
Investigators
Layout table for investigator information
Study Director: Medical Director, MD BioMarin Pharmaceutical
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: BioMarin Pharmaceutical
ClinicalTrials.gov Identifier: NCT04554940    
Other Study ID Numbers: 111-209
First Posted: September 18, 2020    Key Record Dates
Last Update Posted: July 26, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by BioMarin Pharmaceutical:
Dwarfism
Bone Diseases
Bone Diseases, Developmental ACH
Natriuretic Peptide, C-Type
Musculoskeletal Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Achondroplasia
Dwarfism
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Osteochondrodysplasias
Genetic Diseases, Inborn